150 related articles for article (PubMed ID: 37716505)
21. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
22. Frequent BRAF
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
[TBL] [Abstract][Full Text] [Related]
23.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract][Full Text] [Related]
24. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
25. Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.
Ming J; Liu Z; Zeng W; Maimaiti Y; Guo Y; Nie X; Chen C; Zhao X; Shi L; Liu C; Huang T
Int J Clin Exp Pathol; 2015; 8(11):15155-62. PubMed ID: 26823860
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
27. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
[TBL] [Abstract][Full Text] [Related]
28. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.
Finkelstein A; Levy GH; Hui P; Prasad A; Virk R; Chhieng DC; Carling T; Roman SA; Sosa JA; Udelsman R; Theoharis CG; Prasad ML
Histopathology; 2012 Jun; 60(7):1052-9. PubMed ID: 22335197
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis.
Vuong HG; Le HT; Le TTB; Le T; Hassell L; Kakudo K
Pathol Res Pract; 2022 Dec; 240():154180. PubMed ID: 36306725
[TBL] [Abstract][Full Text] [Related]
31. Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors.
Hamatani K; Mukai M; Takahashi K; Hayashi Y; Nakachi K; Kusunoki Y
Thyroid; 2012 Nov; 22(11):1153-9. PubMed ID: 23050789
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M
Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144
[TBL] [Abstract][Full Text] [Related]
33. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
34. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
36. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
[TBL] [Abstract][Full Text] [Related]
37. Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype.
Zhou J; Wang WR; Zhang HF; Gao QQ; Wang WB; Zhu JH; Han YS; Chen J; Ma TH; Zhang XY; Teng XD
Front Endocrinol (Lausanne); 2023; 14():1138100. PubMed ID: 37124750
[TBL] [Abstract][Full Text] [Related]
38. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
39. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas.
Lima J; Trovisco V; Soares P; Máximo V; Magalhães J; Salvatore G; Santoro M; Bogdanova T; Tronko M; Abrosimov A; Jeremiah S; Thomas G; Williams D; Sobrinho-Simões M
J Clin Endocrinol Metab; 2004 Sep; 89(9):4267-71. PubMed ID: 15356020
[TBL] [Abstract][Full Text] [Related]
40. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.
Virk RK; Van Dyke AL; Finkelstein A; Prasad A; Gibson J; Hui P; Theoharis CG; Carling T; Roman SA; Sosa JA; Udelsman R; Prasad ML
Mod Pathol; 2013 Jan; 26(1):62-70. PubMed ID: 22918165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]